BridgeBio to Present Long-Term ATTR-CM Survival Data and Three Posters at ACC
BridgeBio will present long-term survival and disease stabilization results from its Phase 3 ATTRibute-CM OLE trial during a late-breaking oral session at ACC on March 30. The company will also showcase three posters detailing serum transthyretin changes, KCCQ-OS score improvements and real-world treatment patterns.
1. Oral Presentation Details
BridgeBio will present long-term survival benefits and disease stabilization data from its open-label extension of the Phase 3 ATTRibute-CM trial in a late-breaking oral session at the ACC Annual Scientific Sessions on March 30 at 2:33 pm CT. The presentation will be delivered by Prem Soman, M.D., Ph.D., from the University of Pittsburgh School of Medicine.
2. Poster Presentations
Three additional posters will share detailed OLE trial findings: serum transthyretin concentration changes and KCCQ-OS score improvements, early sTTR increases linked to long-term heart failure status, and real-world treatment patterns and preferences in ATTR-CM patients in the United States. These posters will be presented by researchers from Brigham and Women’s Hospital, Medical University of South Carolina and University of Utah between March 28 and 30.
3. Trial Overview and Implications
The ATTRibute-CM open-label extension examines acoramidis’s ability to reduce cardiovascular death and cardiovascular-related hospitalizations in wild-type and variant transthyretin amyloid cardiomyopathy. Positive long-term efficacy and safety readouts could strengthen BridgeBio’s commercial positioning and support broader clinical adoption.